Speakers

Andrew Allars

Andrew Allars

Andrew Allars B.Sc., MBA (56), is CEO of Wyvern Asset Management. WAM is the fund manager of the Wyvern Seed Fund, investing in spin-out opportunities from the Universities of Bristol and Southampton. He is also Managing Partner of venture consultancy, Anauel LLP.He was originally trained in chemistry and biochemistry at the University of Southampton and spent 10 years working in sales and marketing in the bioscience industry, at companies such as Pharmacia LKB and ICI.

After completing an MBA at Cranfield Management School, he entered the venture capital industry in 1990. He was, until 2004, Head of Life Sciences at Prelude Ventures Limited, a specialist venture capital investor in early stage technology companies. During his time at Prelude he was closely involved in several successful start up bioscience companies including Acambis plc (now part of Sanofi), Quadrant Healthcare plc (now part of Vectura plc), Danby Medical Limited (now part of Baxter Inc) and Oxford Biomedica plc.

At Anauel he has worked with a number of venture capitalists, in particular the Dutch group, Life Science Partners, and a number of start-up companies including Azellon Ltd.


Michał Bańka

Michał Bańka

Michał Bańka worked at the Ministry of Economy to manage and mediate implementation of several EU funded programs. Since 2006 his responsibilities have included running the financial departments of three Programs: (1) Improving the Competitiveness of Enterprises, (2) Innovative Economy and (3) Infrastructure and Environment. He has held the positions of Deputy Director, and from 2012 Director of the Department of Business Environment Institution Support of the Polish Agency for Enterprise Development. His responsibilities include: (1) Providing support for business incubators in finding innovative ideas and capital input for “Start-ups”, (2) Support of the ‘Business Angels’ Network, (3) Support for Business Environment Institutions, (4)

Originator, Loan fund managers for micro and small enterprises with the participation of business angel or venture capital fund.

Financing of advisory services that are necessary to attract external investors. His business career is combined with an academic role involving teaching at the Faculty of Political Science at Warsaw University. He is the project manager and general executive of R & D projects of the Ministry of Science and Higher Education and author and co-author of several monographs and scientific articles.


Catherine Beech

Catherine Beech

Dr Catherine Beech OBE is an entrepreneur who focuses on start up companies in the life sciences sector. She began her career working as a doctor within the NHS joining the pharmaceutical industry over 20 years ago. In 1999 Catherine co-founded Cambridge Gateway Fund, an early stage fund that invested primarily in spinouts from UK Universities. From 2006 until 2008 Catherine was CEO of Aitua, a seed investment company that invested in spinouts from the BBSRC facility in Cambridge. Catherine has invested in and taken a position on the board of circa 10 early stage companies helping them to grow and in some cases achieve successful IPO’s or trade sales.

As a member of the Technology Strategy Board, Catherine was instrumental in supporting the UK government to define the UK strategy for Life Sciences. In 2008 she was awarded an OBE for Services to Technology and Innovation.


Marek Borzestowski

Marek Borzestowski

Marek Borzestowski is a serial entrepreneur, founder of successful internet businesses and a partner in the Polish Israeli VC Fund ‐ Giza Polish Ventures. He has over 20 years of experience as a founder and member of the boards of Wirtualna Polska, Gruper.pl, Mind the Kids, InteliWISE and a founder of a first Polish think tank – Sobieski Institute and Sturtup Hub Poland Foundation. Marek is actively investing in companies that focus on digital, mobile, data analytics and biotechnology. He graduated from a Technical University of Gdansk, studied at the University of Wales in Swansea in the UK and in the Nuclear Research Centre in Karlsruhe in Germany.


Chas Bountra

Chas Bountra

Chas is Professor of Translational Medicine in the Nuffield Department of Clinical Medicine and Associate Member of the Department of Pharmacology at the University of Oxford. He is also a Visiting Professor in Neuroscience and Mental Health at Imperial College, London. Chas is an invited expert on several government and charitable research funding bodies, and an advisor for many academic, biotech and pharma drug discovery programmes.

Prior to coming back to Oxford six years ago, Chas was Vice President and Head of Biology at GlaxoSmithKline. He was involved in the identification of more than 40 clinical candidates for many gastro-intestinal, inflammatory and neuro-psychiatric diseases. More than 20 of these molecules progressed into patient studies and more than five of these delivered successful “Proof of Concept” data and hence progressed into late stage development. He was involved in the launch and development of the first treatment for Irritable Bowel Syndrome (Alosetron) and was the first to show that neurokinin NK1 antagonists are anti-emetic in preclinical and clinical studies.

His current interests are i) using X ray structures of novel human proteins to generate small molecule inhibitors, screening in human cells to identify novel targets for drug discovery, and then developing clinical candidates for evaluation in patients, pre-competitively ii) focussing on epigenetic and genetically identified proteins, because these are likely to represent better targets for drug discovery, for many cancer, inflammatory, metabolic and neuro-psychiatric diseases iii) working with colleagues in Oxford to build major programmes in rare diseases and in Alzheimers Disease, and creating a “BioEscalator” for the rapid translation of SGC science and iv) building stronger links with local hospitals, patient groups, regulatory agencies, private investors, CROs, biotechs and large pharma companies, to create a new, more efficient ecosystem for pioneer drug discovery.

Chas believes the SGC has become a leader in human protein structural biology and epigenetics chemical biology, and is arguably one of the most successful open innovation, public – private partnerships in the world. Furthermore, with the many recent local developments (Target Discovery Institute, Kennedy Institute), he believes Oxford is emerging as one of the major academic drug discovery centres in Europe. He has given over 300 invited lectures. In 2012 he was voted one of the “top innovators in the industry”.


Glenn Crocker

Glenn Crocker

Glenn Crocker is the CEO of BioCity – the UK’s leading life sciences business incubator. He is an expert in life science start up market, establishing life science business ecosystems and the repurposing of redundant pharmaceutical facilities. Career highlights:

Glenn has a BSc in Genetics from Nottingham University and a DPhil in Immunology from Oxford University. Following a short time in post-doctoral research he joined Ernst & Young and qualified as a chartered accountant.

With Ernst & Young he focussed on biotech companies in the South of England: then moved with the Practice to Palo Alto, California working with, among others, Alza, Incyte, Gilead and Tularik. He authored the company’s annual life science industry reports. He returned to Cambridge, UK, he headed up the company’s UK Biotech Practice leading its development before taking on the role of CEO at BioCity Nottingham in 2003. During his 10 years at BioCity Nottingham he has grown this ex Boots R&D City Centre site into a profitable business through his innovative approach to business incubation where the focus is on the company and its ability to survive and grow profitably. This approach attracted 96 companies to start life with BioCity and 91% of those companies remain in business and continue to grow.

Glenn was the co-founder of R5 Pharmaceuticals (which was subsequently sold to Aesica) and BioAscent Discovery and has been closely involved in the establishment of Xenogesis and a number of other life science companies.

He has led the expansion of BioCity into Scotland; established collaborations with Boots, a member of Alliance Boots, to create MediCity – the health, beauty and business innovation hub; and was appointed by Astra Zeneca to create a BioHub at its Alderley Park site, Cheshire. BioCity and Glenn have received a number of awards in recognition of these achievements. He is the author of the UK Life Sciences Start-up Report, an annual survey of the UK start up sector and co-founder of the UK Bio-incubation Forum – a leading membership association and independent voice for life science business incubation and accelerated growth, influencing policy at local, national, European and international level.


Janusz Golus

Janusz Golus

Janusz Golus is a Business Development Manager at Philips Healthcare.

He received his M.Sc. and Ph.D. degrees in chemistry from the Jagiellonian University in Kraków. He held two years postdoctoral position at the Marquette University in Milwaukee, United States, where he developed a new method for synthesis of selectively deutered Ru(bPy)³ complexes and their derivatives that enabled the conversion of solar energy into other forms of energy. His research attracted funding from the US Department of Energy and US National Health Institute, and its results were published in several prestigious academic journals, incl. the Journal of American Chemical Society.

From academics, Janusz transitioned into healthcare industry. Between 1995 and 1997 he successfully introduced Abbott pharmaceuticals, incl. Klacid and Forane, to the Polish market, by engaging and managing a team of sales representatives, first at Gremi Farm and later directly at Abbott Laboratories. In 1997 he transferred to GE Healthcare where he was an Account Manager responsible for sales of diagnostic equipment in southeastern Poland. In this capacity he contributed to the establishment and growth of several diagnostic imaging companies, incl. Helimed, Euromedic, Voxel and Med-Sport.

In 1999, Janusz and his wife Monika cofounded Scanmed, today the largest private healthcare clinic in southeastern Poland.

In 2008 he transferred to Philips, where he is currently assisting Philips clients and their partners in the development of innovative healthcare services and research projects by leveraging EU and national funding for technology transfer projects.

He resides in Kraków, but spends his weekends in a small village in Beskid Wyspowy. He enjoys traveling, reading books and gardening. He has been happily married for 37 years and has three sons.

He can be contacted at janusz.golus[at]philips.com


Leszek Grabarczyk

Leszek Grabarczyk

Leszek Grabarczyk, Deputy Director, National Centre for Research and Development (NCBR)

Since 2011, Leszek Grabarczyk has been Deputy Director of the National Centre for Research and Development (NCBR) – a government agency with an annual budget of PLN 5.5bn which supports the R&D sector in Poland. He is responsible for the development and implementation of programmes that promote innovation and research commercialisation. In 2014, the NCBR has launched BRIdge – a family of programmes that constitute Poland’s first ever system of financing new technologies by the public-private partnership while using private equity funds together with the world’s largest entities of this type. Thanks to the activities of the NCBR, Poland’s R&D expenditure in 2012 achieved a record result of PLN14.4 billion – almost 23% more than in the previous year.


Jeffery Grady

Jeffery Grady

Jeffery Grady has over 25 years building businesses across a variety of sectors. He is currently COO of Proteon Pharmaceuticals S.A. of Poland, where he is assisting the CEO in speeding up development, raising capital and developing the commercialization approach of the company.

Mr. Grady has been involved in a large number of startups and significant ‘turnarounds.’ The start-ups were in several sectors; the ‘turnarounds’ ranged from a large multinational with sales in 12 countries to a smaller technology company.

Mr. Grady has also been in Private Equity (COO of Copernicus Capital-an Affiliate of Advent in Poland); High-Tech Venture Capital (as a member of the Investment Committee of an Israeli High-Tech VC Fund), and as an ‘active’ Angel investor in Poland and the USA.

Mr. Grady has a B.A. and M.A. from the University of Virginia and an MBA from Yale University. His early career involved technology evaluation and research methods — including co-authoring an article on the Evaluation of Anti-Tank Warhead technology.


Regina Hodits

Regina Hodits

Regina Hodits studied chemical engineering in Vienna and holds a PhD in biochemistry. She was a researcher at the University of Vienna and the MRC Centre for Protein Engineering before joining McKinsey. She focuses on early-stage and growth deals in Life Sciences. Until January 2010, she led the life sciences efforts of Atlas Venture in Europe where she was the founding investor in Bicycle Therapeutics, F-star and Jenavalve. Regina served on several Boards, including the Board of U3 Pharma, which was acquired by Daiichi Sankyo Co. Ltd in 2008 and Novamed, which was acquired by SciClone in 2010. From 2000 to 2004, while working for Apax Partners, she was responsible for healthcare investments in Germany and was closely involved in investments such as Genmab and Silence Therapeutics. She is currently a General Partner at Wellington Partners and represent the Wellington Partners funds on the Board of Middle Peak Medical, Ayoxxa, Sapiens and Atopix, and is an external director at GlaxoSmithKline’s Respiratory TA Board.


Krzysztof Jakubczak

Krzysztof Jakubczak

Krzysztof Jakubczak is a graduate from the Institute of Optoelectronics of the Military University of Technology, Warsaw, Poland. He achieved his PhD in the technical sciences from the Czech Technical University in Prague. His technical background is in military technologies, lasers, optics (classical, X-ray and EUV), infrared technology, light modulation and detection, secondary sources for nanolithography, vacuum systems and spectroscopy. Krzysztof is an experienced R&D engineer. As Deputy Project Manager he worked on design of HiLASE laser research center and establishment of cooperation with the parties. He led the R&D team as a Research Program Leader working on development of lasers for industrial applications. His commercial experience covers production engineering and R&D projects in medical devices as well as new startups. In march 2014 he joined LSBC as the Operations Director within Bridge Mentor Project to commercialize Life Science inventions in Poland. He manages the team of commercialization experts and assesses commercial potential of medical devices and technical projects.


Roland Kozlowski

Roland Kozlowski

Roland Kozlowski received a first class honours degree from the University of Bath and a PhD from the University of Cambridge. He is a bioentrepreneur who has worked in the industry for approaching two decades. Roland has held a number of operational roles including most recently Chief Executive Officer and a founder of Lectus Therapeutics Limited (investor exit via asset sale to UCB in Q4, 2011), Chief Executive Officer and co-founder of Sense Proteomic Limited (trade sale to Procognia Limited in Q1, 2003). In the mid 1990s Roland worked with Oxford Molecular PLC on their cornerstone deal he negotiated with Yamanouchi Pharmaceutical Co., Ltd. During his career Roland has gained considerable transactional experience ranging from company sale, purchase, financing and in- and out-licensing and commercialisation of technology. In the past Roland ran a Research Groups at the University of Oxford and University of Bristol where subsequently he was a Visiting Industrial Professor. He has published and patented in the field of ion channel physiology and pharmacology. Roland has served on the boards of a number of companies including the Bio-Industry Association in the UK. He remains a director of Lectus Therapeutics Limited and is presently non-executive director of London Genetics Limited which operates in the personalised medicine space, Chief Strategy Officer of BTM Mazowsze Sp. z o. o. a company set up to commercialize innovation emerging from the leading life science research institutions in Warsaw.


 

Klaus Martin

Klaus Martin is the Senior Director of Polpharma Biologics leading its global business and product and development activities. With his broad experience in strategy and development of Biosimilars and Biobetters. Klaus joined Polpharma to set up its Biologics business in October 2010. Prior to Polpharma, for eight years he held global management positions at Sandoz Biopharmaceuticals, first as Development Project Leader, e.g. for Sandoz’ filgrastim and, a.i. for their rituximab biosimilars, then as Head of Global Pre-clinical and Clinical development and finally as Head of BD&L and Portfolio Management as a member of the Biopharmaceuticals Executive Committee. His teams helped bring to the market Sandoz’ first three biosimilars in the EU, US and Japan.Klaus is a biochemist by training and holds a PhD in Pathology from the University of Cambridge. Before joining the pharmaceutical industry, he spent three years as a strategy consultant with OC&C advising international clients in a variety of industries.


Edyta Niemczyk

Edyta Niemczyk

Edyta Niemczyk graduated from Intercollegiate Faculty of Biotechnology, University of Gdańsk and Medical University of Gdańsk. She received a PhD in molecular biology from Medical University of Gdańsk, supervised by excellent scientist from Nagoya Medical University in Japan – Prof. Takashi Wakabayashi, who was a famous specialist in pathology of mitochondria.

In order to follow the career pathway she envisaged, she applied for the Postdoctoral Research Associate position at the University of Liverpool in UK with the positive outcome. During the two-year contract she was acquainted with Single Nucleotide Polymorphism (SNP) genotyping using Illumina arrays for the purpose of Familiar Pancreatic Cancer investigation. The next step for her career was to participate in the project that would consider SNPs analysis using the most advanced technology and analysis tools. That opportunity was given to her at the University of Birmingham, when she was appointed for the Postdoctoral Fellow position where she was passionately analyzing association of the genetic loci with acute anterior uveitis onset.

Edyta is experienced geneticist perfectly joining the passion for the science and its commercialization. Her key responsibilities at LSBC as the Junior Commercialization Expert are to assess properly the scientific and commercial strengths of analyzed projects.


Lukasz Nieradko

Lukasz Nieradko

Dr. eng. Lukasz Nieradko

Director of Business Development Department

Lukasz Nieradko is graduated in electronics of Wroclaw University of Technology. He received MSc and PhD degree in 1996 and 2002 respectively. His doctoral thesis – defended with honors – considered development of CMOS compatible technology of the first in the world integrated on-chip microcolum for gas chromatography with porous silicon active layer acting as stationary phase. This technology opened possibilities to built miniature, portable systems for µTAS type gas analyzer for coal mine industry. During his studies, he participated as in research programs, focused on development of technology of silicon pressure sensors, accelerators and MEMS devices. His research activities were awarded on several conferences, he won team prize of Association of Polish Electrical Engineers SEP, prize of President of Warsaw University of Technology. Dr Nieradko is a post-fellow of Foundation of Polish Science. Since 2001 to 2003 he joined University of Franche-Comte, as post-doc fellow of Marie Curie Individual Fellowship, where he has conducted R&D activities in the field of integrated microoptics – MOEMS, working of novel types of movement, vibration and pressure sensors in the frame of 5th FP – OCMMM (Optical Characterization Methods of MEMS Manufacturing). In 2004 he joined CNRS (Centre National d’Recherche Scientific) as Research Engineer, working in research projects of DGA (Direction Générale de l’Armement), CNES (Centre National d’Études Spatiales) and ANR (Agence Nationale de la Recherche) on integrated on-chip atomic clock. His research interest on integrated microoptics were realized in FP6 – Network of Excellence in Micro Optics (NEMO) – project developing various MOEMS devices, technologies of glass and plastic optical microcomponents of miniature confocal microscope. Dr Nieradko is author of patent and scientific publications. He is a member of PTTS (Polish Society of Sensors Technology) and MCFA (Marie Curie Fellow Association).

Dr Nieradko joined WCB EIT+ on June 2008 as Coordinator of Research and Infrastructure Development in field of nanotechnology. Currently he holds a position of Director of Business Development Department. He is responsible i.a. for commercialization, establishing collaborations and alliances with companies, development of new commercial projects, as well as an implementation of new technologies to Partners.


Marta Oseka

Marta Oseka

Marta Osęka has dual educational background in the field of Economics and Production Engineering (Warsaw University of Technology). Since 2005, she has dealt with collaboration between science and business. She focuses on obtaining financing for R&D projects, creating business strategies, optimizing an investment costs and project management. She has been collaborated with the Deloitte (as a Manager at the R&D and Government Incentives Department), and with the VC funds – INVESTIN (as a Project and Technology Manager), also with many Polish and foreign R&D centres (as a research specialist, a project coordinator or an advisor).

Marta’s key responsibility at the LSBC as a Business Development Associate is to provide essential support for research projects in business development stage.


Maciej Paszewski

Maciej Paszewski

Maciej Paszewski studied chemistry in Warsaw and holds a PhD in organic chemistry. He was a researcher at the Northwestern University and the Institut of Physical Chemistry Polish Academy of Sciences before joining Orenore, a polish VC found. In Orenore he was responsible for acquisition and evaluation of projects in the area of life science. Maciej led to creation of Nanoxide – a start-up company developing new fluorescent probes for biology and medicine based on newly discovered zinc clusters. As a director in Nanoxide he was responsible for R&D strategy, IP protection, market and competition analysis and raising external funds. Maciej collaborated with AstraZeneca as a clinical trial monitor.

In 2013 he has joined LSBC. He is currently a Senior Commercialization Associate at LSBC where he is responsible for project evaluation, mentoring and writing business proposals. He participates in Bridge Mentor jointly implemented by LSBC and The National Center for Research and Development.


Steven Powell

Steven Powell

Steven Powell, Operational Partner, Gilde Healthcare

Steven has over 25 years operational and investment experience in pharmaceutical and life science R&D at companies including Beecham Pharmaceuticals (GSK), Whatman, Chiroscience, Celsis, Active Biotech, KS Biomedix and Plethora Solutions. During his operational career he has held four CEO roles, two in public companies. He joined Gilde Healthcare, a pan-European life sciences investment fund, in 2003. Steven has co-founded 4 companies of which 2 have been sold and concluded over 40 licensing agreements and 7 M&A transactions. Steven graduated in microbiology from the University of Wales and was awarded a PhD from the University of Aberdeen.


Pawel Przewiezlikowski

Pawel Przewiezlikowski

Pawel Przewiezlikowski, co-founded Selvita in 2007 and is the Chief Executive Officer of the company, responsible for strategic management, business and corporate development. He is also the Chief Executive of BioCentrum, Selvita’s daughter company. Mr. Przewiezlikowski is a member of the Economic Council of the Malopolska (Krakow) region as well as of the Malopolska Innovation Council. From 1994 to 2007 he worked at ComArch, a Polish information technology company. As a management board member since 1996, he was responsible for the divisions offering solutions for the pharmaceutical, banking, manufacturing and services industries and took part in the organic transformation of a university spin-off to the largest organically grown IT company in Central and Eastern Europe, employing over 2 700 people in 20 countries. During his time at ComArch in 1999-2000 he was also the co-founder and the first CEO of Interia.pl, the third largest portal in Poland. Mr. Przewiezlikowski holds an MBA from the joint program of the University of Teesside (United Kingdom) and Krakow School of Economics (Poland) as well as master degree in computer science from AGH Technical University in Krakow.


Mike Romanos

Mike Romanos

Mike Romanos is CEO and founder of Crescendo Biologics Ltd, a VC-backed Cambridge based company that has developed an innovative transgenic platform for generating human single domain antibody therapeutics. He has 25 years’ biotech and pharmaceutical industry experience in biologic and NCE drug discovery across several therapeutic areas, starting with Wellcome Biotech, an early pioneer in UK biotechnology, in the 1980s.

Previous to his current role, Mike held leadership positions for over 10 years in GlaxoSmithKline R&D, building and managing global Discovery organisations that made a major impact in targets, technology and pipeline projects. In particular, Mike played a key role in establishing GSK’s antibody lead discovery capability which generated a pipeline of in-house monoclonal antibodies, several of which are in clinical development.

Mike holds a degree in Natural Sciences from Cambridge University, a PhD in Molecular Virology from Imperial College, and undertook postdoctoral research in Virology at the MRC’s National Institute for Medical Research and in Yeast Biotechnology at Leicester Biocentre. He is currently a panel member of the MRC’s Developmental Pathway Funding Scheme, which funds translational studies through preclinical and early clinical development, and a Fellow of the Society of Biology.


Benjamin Thiering

Benjamin Thiering

Benjamin Thiering joined the Health Care Industries Unit at Berlin Partner for Business and Technology, the Berlin Economic Development Agency, in 2013. He holds a degree in economic geography from Humboldt-Universität zu Berlin and started his life science career with his thesis in the Business Development of Fraunhofer Institute for Cell Therapy and Immunology (IZI) in Leipzig in 2010. After working in the economic development for the German state of Hesse, Benjamin is now responsible for supporting Biotech & Pharma companies in their relocation and start-up ventures in the German Capital region.


Alexander Yule

Alexander Yule

Dr Alexander Yule (Principal, Alexander Yule Consulting). Alexander Yule is a commercial and corporate support professional with over 23 years’ experience at senior executive level as either an employee, interim manager or long term advisor within private and public life science and pharmaceutical companies in the UK, Scandinavia and North America. He has been involved in the commercialisation of products and technologies across oncology, CNS, urology, infectious disease, clinical diagnostics, medical devices and OTC/consumer healthcare. Alex particularly enjoys working with pre-money/start-up and small-cap companies but also works with mid-cap and global healthcare companies. He has supported numerous successful LSE/AIM listings, private placements and M&A transactions.


Dominik Zietkowski

Dominik Zietkowski

Dominik Zietkowski is a Research and Development Director at BLIRT S.A., a polish innovative biotechnology company located in Gdansk. He received his M.Sc. in biotechnology form the University of Gdansk and a Ph.D. degree in biophysics from the University of London. For 4,5 years he held doctoral and postdoctoral positions at the Institute of Cancer Research and the Royal Marsden Hospital in London where he was working on biomarker discovery and an innovative anticancer compounds development. In 2011 he joined R&D team at Blirt S.A., initially as a project manager, then as a Head of R&D, where he was responsible for the development of company’s in house drug discovery, R&D projects in oncology and antifungals. He also serves as a deputy CEO in BS-154 sp. z o.o. and Transmedium sp. z o.o., Blirt’s two spin-off companies developing an innovative oncology drug candidate and a transplantology dedicated medical device, respectively.


Romeer Fernandes
 

Romeer Fernandes

Romeer Fernandes is a commercial leader with a 15-year track record of successfully building medical devices and pharmaceutical businesses in Europe and Asia with blue-chip multinationals (e.g. Medtronic, GlaxoSmithKline) and start-ups. He currently works as an independent consultant in interim management roles with medtech start-ups in Switzerland. He recently developed and rolled-out the Go-to-market strategy for Symetis, a Swiss start-up that launched an innovative trans-cathteter valve, achieving the first million dollars in revenue within 3-months of CE approval. Romeer has a degree in Molecular Biology (Univ of Cambridge, UK) and an MBA (IMD, Switzerland)


Mariusz Olejniczak
 

Mariusz Olejniczak

Mariusz Olejniczak is General Manager and shareholder of Assign Clinical Research Sp. z o.o. Assign Clinical Research Sp. z o.o. is a member of Assign Group and The Biosimilars Group. Both organizations provide services especially in clinical operations and manufacturing of investigated medicinal products. In addition, Mariusz works in the field of e/m-Health as CEO of e-clincial start-up Monitor-CR sp. z o.o. and provides consulting services for companies and start-ups developing pharmaceuticals and medical devices. He was orig¬i¬nally trained in biotechnology and subsequently was work¬ing in science and mar¬ket¬ing in the medical devices and transplantation fields. Mariusz is member of the board of Association for Good Clinical Practice in Poland.


Bogusław Sieczkowski
 

Bogusław Sieczkowski

Mr. Boguslaw Sieczkowski is a co-founder of Selvita and currently holds the position of the Executive Vice President, as well as the Chief Operating Officer. Mr. Sieczkowski has a solid education and over 15 years of experience in management. His career was initiated in the middle nineties supervising computerization of companies within Bahlsen group. Since 2000 as a board member of Comarch Internet Ventures S.A. he developed the first ASP Services platform in Poland. Till 2007, as a Vice President of Comarch S.A. he was in charge of the largest subsector (250 people) delivering product for leading scientific and finance institutions. Mr. Sieczkowski holds an MBA from joint programme of the University of Teesside (United Kingdom) and Krakow School of Economics (Poland), master degree in computer science from Jagiellonian University in Krakow as well as Project Management Professional certificate issued by Project Management Institute (United States). His hobbies are skiing and tourism.


Mark Treherne
 

Mark Treherne

Mark has been actively involved in the biopharmaceutical industry for 25 years and was a co-founder and Chief Executive of Cambridge Drug Discovery Limited, leading the Company’s acquisition by BioFocus plc, where he then became a Commercial Director, driving significant growth of its profitable services business. Mark has now served on the Boards of 13 private and public biopharmaceutical companies and is currently on the Boards of Cyclofluidic, Domain Therapeutics, Population Genetics Technologies and Senexis. Dr Treherne has now helped raise more than £140 million for various biopharmaceutical businesses over the last decade. Mark was also formerly Chairman of ERBI Limited, which is a not-for-profit organisation that represents the biotechnology companies based around Cambridge in the East of England. Mark initially trained as a neuroscientist and electrophysiologist at Cambridge University. Mark joined the Life Science Investment Organisation as Chief Executive, following its formation by UK Trade and Investment.


Marcin Szumowski
 

Marcin Szumowski

Marcin Szumowski is serial entrepreneur. He received his MS and PhD degrees from the University of Illinois and earned an MBA degree in entrepreneurship and international finance. Following a successful research career in the United States, Marcin has been involved in technology transfer and start-up companies since 2000 and has co-founded and managed five start-ups, including a medical diagnostics company Medicalgorithmics, where he was President and CEO during 2005-2010. Medicalgorithmics SA is now traded on the Warsaw Stock Exchange with a market cap of approx. $230M and its products are sold globally. Since 2012 he is President & CEO of OncoArendi, a Polish innovative biopharmaceutical company dedicated to developing and commercializing novel therapeutics for neoplastic and inflammatory diseases. Over the last 15 years Marcin has managed approx. 40 R&D and investment projects with a total value of over 200M euro.


Adam Kruszewski
 

Adam Kruszewski

Adam Kruszewski is an expert and manager, with over 25 years of management and business development experience in the area of: Drug/Devices Development Market, Health Care Markets, Financial Markets. Invented and developed a number of business projects and support activities For 9 years President & Shareholder of KCR – the fastest growing CRO in CEE Region. Currently CEO/Chairman & main shareholder of pHase2microtechnology, a high-tech company based in Pittsburgh, PA.